Total Payments
$1,334
2024 Payments
$536.48
Companies
32
Transactions
62
Medicare Patients
2,676
Medicare Billing
$427,964
Payment Breakdown by Category
Food & Beverage$1,189 (89.1%)
Education$119.84 (9.0%)
Gifts$25.00 (1.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,189 | 58 | 89.1% |
| Education | $119.84 | 3 | 9.0% |
| Gift | $25.00 | 1 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $236.82 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $152.59 | 7 | $0 (2024) |
| Daiichi Sankyo Inc. | $95.07 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $85.00 | 1 | $0 (2020) |
| Genentech USA, Inc. | $66.34 | 4 | $0 (2021) |
| GENZYME CORPORATION | $53.18 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $52.95 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $50.14 | 3 | $0 (2024) |
| PFIZER INC. | $49.35 | 3 | $0 (2024) |
| Foundation Medicine, Inc. | $44.88 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $536.48 | 24 | Novartis Pharmaceuticals Corporation ($112.64) |
| 2023 | $277.60 | 13 | Celgene Corporation ($89.46) |
| 2022 | $77.88 | 4 | Celgene Corporation ($38.26) |
| 2021 | $92.28 | 6 | AstraZeneca Pharmaceuticals LP ($21.20) |
| 2020 | $116.85 | 3 | Astellas Pharma US Inc ($85.00) |
| 2019 | $141.19 | 7 | Foundation Medicine, Inc. ($44.88) |
| 2018 | $68.23 | 3 | Seattle Genetics, Inc. ($32.09) |
| 2017 | $23.19 | 2 | Genentech USA, Inc. ($12.19) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/02/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.99 | General |
| Category: Hematology | ||||||
| 10/15/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $33.78 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $60.18 | General |
| 09/03/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/02/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: Immunology | ||||||
| 07/01/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/14/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.93 | General |
| Category: Hematology | ||||||
| 05/03/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: HEMATOLOGY | ||||||
| 04/18/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 03/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.78 | General |
| Category: Oncology | ||||||
| 02/29/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Hematology | ||||||
| 02/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Oncology | ||||||
| 01/31/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Immunology | ||||||
| 01/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Immunology | ||||||
| 12/15/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 673 | 1,205 | $292,801 | $107,985 |
| 2022 | 10 | 719 | 1,292 | $295,482 | $120,318 |
| 2021 | 9 | 681 | 1,226 | $265,338 | $113,244 |
| 2020 | 9 | 603 | 1,004 | $225,016 | $86,416 |
Total Patients
2,676
Total Services
4,727
Medicare Billing
$427,964
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 255 | 478 | $116,154 | $40,668 | 35.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 114 | 236 | $80,948 | $30,067 | 37.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 76 | 191 | $26,167 | $11,594 | 44.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $18,524 | $6,879 | 37.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 59 | $11,741 | $5,142 | 43.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 48 | 48 | $12,432 | $4,741 | 38.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 23 | $8,717 | $2,944 | 33.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $7,314 | $2,395 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 39 | $6,708 | $1,978 | 29.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 25 | 64 | $4,096 | $1,578 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 234 | 445 | $96,040 | $38,347 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 118 | 255 | $76,055 | $33,781 | 44.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 67 | 169 | $33,713 | $13,292 | 39.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 71 | 74 | $28,406 | $11,108 | 39.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 146 | $20,100 | $7,970 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $16,120 | $6,408 | 39.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 62 | $9,264 | $3,260 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $7,830 | $2,891 | 36.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 17 | $4,430 | $1,763 | 39.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 29 | 59 | $3,524 | $1,497 | 42.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 237 | 475 | $95,950 | $40,420 | 42.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 275 | $75,075 | $35,716 | 47.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 69 | 137 | $27,400 | $10,982 | 40.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 60 | 61 | $23,729 | $9,175 | 38.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 70 | 78 | $10,686 | $4,210 | 39.4% |
About Dr. James Code, M.D
Dr. James Code, M.D is a Hematology & Oncology healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982730081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Code, M.D has received a total of $1,334 in payments from pharmaceutical and medical device companies, with $536.48 received in 2024. These payments were reported across 62 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($1,189).
As a Medicare-enrolled provider, Code has provided services to 2,676 Medicare beneficiaries, totaling 4,727 services with total Medicare billing of $427,964. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Louisville, KY
- Active Since 02/26/2007
- Last Updated 12/02/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982730081
Products in Payments
- REBLOZYL (Biological) $120.91
- Enhertu (Drug) $64.50
- Fabhalta (Drug) $64.43
- KEYTRUDA (Biological) $50.14
- Perjeta (Biological) $47.05
- FOUNDATIONONE (Device) $44.88
- ELZONRIS (Drug) $43.89
- Lenvima (Drug) $34.20
- ELAHERE (Drug) $33.78
- SARCLISA (Biological) $33.51
- INLYTA (Drug) $33.25
- VONJO (Drug) $32.37
- ADCETRIS (Biological) $32.09
- INJECTAFER (Drug) $30.57
- OXBRYTA (Drug) $28.75
- LUTATHERA (Drug) $25.46
- G8 Elution Buffer No. 1, 800mL (Medical Supply) $25.00
- SCEMBLIX (Drug) $22.75
- YONSA (Drug) $20.72
- LONSURF (Drug) $20.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Louisville
Goetz Kloecker, Md, MD
Hematology & Oncology — Payments: $761,985
Hematology & Oncology $761,985
Vivek Sharma, Md, MD
Hematology & Oncology — Payments: $594,741
Hematology & Oncology $594,741
Dr. Khuda Khan, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $446,138
Hematology & Oncology $446,138
Dr. Jeffrey Hargis, M.d, M.D
Hematology & Oncology — Payments: $430,805
Hematology & Oncology $430,805
Dr. Joseph Maly, M.d, M.D
Hematology & Oncology — Payments: $43,035
Hematology & Oncology $43,035
Dr. Emmanuel Nidhiry, M.d, M.D
Hematology & Oncology — Payments: $40,629
Hematology & Oncology $40,629